BCHE and Alzheimer disease: Until recently, the majority of FDA-approved AD drugs on the market include cholinesterase inhibitors and a single NMDA antagonist, which solely tackle the symptoms of AD and neglect the underlying mechanisms of the disease (Wang and Reddy, 2017; Breijyeh and Karaman, 2020; Kuns et al., 2022).